药物性肝损伤发生机制的研究进展

摘要/Abstract

摘要： 药物性肝损伤（drug induced liver injury，DILI）是全球范围内常见的药品不良反应，也是临床实践中一直尚未解决的问题，其发病率和致死率逐年升高。DILI的发生可能是多种因素共同作用的结果，至今尚未完全阐明。本研究通过查阅相关文献对药物性肝损伤机制的研究进展进行综述，以期为其临床科学预防、诊断和治疗提供参考。

关键词: font-size:medium, ">药物性肝损伤；发生机制；免疫反应；线粒体损伤；基因多态性；胆汁酸稳态失衡；自噬；炎症应激

Abstract: Drug induced liver injury (DILI) is a common adverse drug reaction worldwide and an unresolved problem in clinical practice， with its incidence and lethality increasing year by year.The occurrence of DILI may be the result of a combination of factors， which have not been fully elucidated so far. In this study, we reviewed the research progress on the mechanism of drug-induced liver injury by reviewing the related literature, aiming to provide a reference for its prevention, diagnosis, and treatment in clinical science.

Key words: font-size:medium, ">Drug-induced liver injury；Mechanism；Immune response； Mitochondrial damage； Genetic polymorphism； Bile acid homeostatic imbalance； Autophagy； Inflammatory stress

中图分类号:

马璟婷1, 2, 宋沧桑1, 2, 李兴德1, 2, 毛盼盼1, 马雪娇1. 药物性肝损伤发生机制的研究进展[J]. 中国药物评价, 2024, 41(2): 132-135.

MA Jing-ting1, SONG Cang-sang1, 2, LI Xing-de1, 2, MAO Pan-pan1, MA Xue-jiao1. Progress in the Study of the Mechanism of Drug-induced Liver Injury[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2024, 41(2): 132-135.

参考文献

[1] 于乐成，茅益民，陈成伟. 药物性肝损伤诊治指南[J]. 中国病毒病杂志， 2015， 5(5): 321-341.
     [2] Katarey D， Verma S. Drug-induced liver injury[J]. Clin Med (Lond)，2016， 16(Suppl 6): s104-s109.
     [3] Li X， Tang J， Mao Y. Incidence and risk factors of drug-induced liver injury[J]. Liver Int， 2022， 42(9): 1999-2014.
     [4] Rani J， Dhull SB， Rose PK， et al. Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective[J]. Phytomedicine， 2024， 122: 155142.
     [5] Giacomini KM，Huang SM， Tweedie DJ， et al. Membranetransporters in drug development[J]. Nature Reviews Drug Discovery， 2010，9(3)：215-236.
     [6] Corsini A， BortoliniM.. Drug-induced liver injury: therole of drug metabolism and transport[J]. Journal of ClinicalPharmacology， 2013， 53(5): 463-474.
     [7] Jaeschke H， McGill MR， Ramachandran. Oxidantstress， mitochondria， and cell death mechanisms in druginduced liver injury: lessons learned from acetaminophen hepatotoxicity[J]. Drug Metabolism Reviews， 2012， 44(1): 88-106.
     [8] Ju C， Reilly T. Role of immune reactions in drug-inducedliver injury (DILI)[J]. Drug Metabolism Reviews， 2012， 44(1): 107-115.
     [9] Van der Heide D， Weiskirchen R， Bansal R. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases[J]. Front Immunol， 2019， 10: 2852.
     [10] Cho T， Uetrecht J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction[J]. Chem Res Toxicol， 2017， 30(1): 295-314.
     [11] Bourdi M， Chen W， Peter RM， et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis[J]. Chem Res Toxicol， 1996， 9(7): 1159-1166.
     [12] Kuwayama M， Uchino K， Takayoshi K， et al. Immunosuppressant therapy successfullyimproved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor:a case report[J]. Oncol Lett， 2016， 11(1): 85-88.
     [13] Tiegs G， Lohse AW. Immune tolerance:what is unique about the liver[J]. J Autoimmun， 2010， 34(1): 1-6.
     [14] Pessayre D， Fromenty B， Berson A， et al. Central role of mitochondria in drug-induced liver injury[J].Drug Metab Rev， 2012， 44(1): 34-87.
     [15] Schumacher JD， Guo GL. Mechanistic review of drug-induced steatohepatitis[J]. Toxicol Appl Pharmacol， 2015， 289(1): 40-47.
     [16] West AP. Mitochondrial dysfunction as a trigger of innate immune responses and inflammation[J]. Toxicology， 2017， 391: 54-63.
     [17] Petros Z， Makonnen E， Aklillu E. Genome-wide association studies for idiosyncratic drug-induced hepatotoxicity:looking back-looking forward to next-generation innovation[J]. Omics， 2017， 21(3): 123-131.
     [18] Grove JI， Aithal GP. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology[J]. Expert Opin Drug Metab Toxicol， 2015， 11(3): 395-409.
     [19] Daly AK， Aithal GP， Leathart JB， et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7， CYP2C8， and ABCC2 genotypes[J]. Gastroenterology， 2007， 132(1): 272-281.
     [20] Ciccacci C， Borgiani P， Ceffa S， et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique[J]. Pharmacogenomics， 2010， 11(1): 23-31.
     [21] Arafa MH， Atteia HH. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity[J]. Toxicol Appl Pharmacol， 2018， 346: 37-44.
     [22] Kolari c＇ TO， Nin cˇevi c＇ V， Smoli c＇ R， et al. Mechanisms of Hepatic Cholestatic Drug Injury[J]. J Clin Transl Hepatol， 2019， 7(1): 86-92.
     [23] Li M， Cai SY， Boyer JL. Mechanisms of bile acid mediated inflammation in the liver[J]. Mol Aspects Med， 2017， 56: 45-53.
     [24] Czaja MJ， Ding WX， Donohue TM Jr， et al. Functions of autophagy in normal and diseased liver[J]. Autophagy， 2013， 9(8): 1131-1158.
     [25] Ramachandran A， Jaeschke H. Acetaminophen hepatotoxicity: A mitochondrial perspective[J]. Adv Pharmacol， 2019， 85:195-219.
     [26] Chaabane W， Appell ML. Interconnections between apoptotic and autophagic pathwaysduring thiopurine-induced toxicity in cancer cells: the role of reactive oxygen species[J]. Oncotarget， 2016， 7(46): 75616-75634.
     [27] Qu X， Gao H， Tao L， et al. Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats[J]. J Toxicol Sci， 2019， 44(3): 167-175.
     [28] Volarevic V， Misirkic M， Vucicevic L， et al. Metformin aggravates immune-mediated liver injury in mice[J]. Arch Toxicol， 2015， 89(3): 437-450.
     [29] Jiang W， Liu J， Li P， et al. Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury[J]. Oncotarget， 2017， 8(20): 33252-33264.
     [30] Russmann S， Kullak-Ublick GA， Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity[J]. Curr Med Chem， 2009， 16(23): 3041-3053.
     [31] Ganey PE， Luyendyk JP， Maddox JF， et al. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor[J]. Chem Biol Interact， 2004， 150(1): 35-51.
     [32] Tukov FF， Luyendyk JP， Ganey PE， et al. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury[J]. Toxicol Sci， 2007， 100(1): 267-280.
     [33] Lu J， Jones AD， Harkema JR， et al. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha[J]. Toxicol Sci， 2012， 125(1): 126-133.
     [34] Luyendyk JP， Shaw PJ， Green CD， et al. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine[J]. J Pharmacol Exp Ther， 2005， 314(3): 1023-1031.